Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor

Shaker A. Mousa, Joel J. Bergh, Emie Dier, Abdelhadi Rebbaa, Laura J. O'Connor, Murat Yalcin, Ahmad Aljada, Evgeny Dyskin, Faith B. Davis, Hung Yung Lin, Paul J. Davis

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Thyroid hormone has been recently shown to induce tumor growth and angiogenesis via a plasma-membrane hormone receptor on integrin αVβ3. The receptor is at or near the Arg-Gly-Asp (RGD) recognition site on the integrin that is important to extracellular matrix (ECM) protein and vascular growth factor interactions with the integrin. In the present study, we examined the possibility that tetraiodothyroacetic acid (tetrac), a deaminated, non-agonist thyroid hormone analog that binds to the integrin receptor, may modulate vascular growth factor-induced angiogenesis in the absence of thyroid hormone. Angiogenesis models were studied in which VEGF or FGF2 (1-2 μg/ml) induced tube formation in human dermal microvascular endothelial cells (HDMEC), stimulated new blood vessel branch formation in the chick chorioallantoic membrane (CAM) and induced angiogenesis in the mouse matrigel model. In all models, tetrac (1-10 μM) and at 10 μg in mouse matrigel inhibited the pro-angiogenesis activity of VEGF and FGF2 by more than 50%. RT-PCR revealed that tetrac (1-3 μM) decreased abundance of angiopoietin-2 mRNA, but not angiopoietin-1 mRNA, in VEGF-exposed endothelial cells, suggesting that specific angiogenic pathways are targeted by tetrac. Tetrac is a novel, inexpensive small molecule whose anti-angiogenic activity in the present studies is proposed to reflect inhibition, via the integrin RGD recognition/thyroid hormone receptor site, of crosstalk between plasma-membrane vascular growth factor receptors and integrin αVβ3.

Original languageEnglish
Pages (from-to)183-190
Number of pages8
JournalAngiogenesis
Volume11
Issue number2
DOIs
Publication statusPublished - Jun 2008
Externally publishedYes

Fingerprint

Fibroblast Growth Factor 2
Fibroblasts
Integrins
Vascular Endothelial Growth Factor A
Ligands
Molecules
Acids
Endothelial cells
Cell membranes
Thyroid Hormones
Intercellular Signaling Peptides and Proteins
Hormones
Blood vessels
Endothelial Cells
Crosstalk
Cell Membrane
Angiopoietin-2
Angiopoietin-1
Chorioallantoic Membrane
Tumors

Keywords

  • Angiogenesis
  • Growth factors
  • Integrin
  • Tetrac
  • Thyroid hormone

ASJC Scopus subject areas

  • Cancer Research
  • Pathology and Forensic Medicine
  • Clinical Biochemistry
  • Polymers and Plastics

Cite this

Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. / Mousa, Shaker A.; Bergh, Joel J.; Dier, Emie; Rebbaa, Abdelhadi; O'Connor, Laura J.; Yalcin, Murat; Aljada, Ahmad; Dyskin, Evgeny; Davis, Faith B.; Lin, Hung Yung; Davis, Paul J.

In: Angiogenesis, Vol. 11, No. 2, 06.2008, p. 183-190.

Research output: Contribution to journalArticle

Mousa, SA, Bergh, JJ, Dier, E, Rebbaa, A, O'Connor, LJ, Yalcin, M, Aljada, A, Dyskin, E, Davis, FB, Lin, HY & Davis, PJ 2008, 'Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor', Angiogenesis, vol. 11, no. 2, pp. 183-190. https://doi.org/10.1007/s10456-007-9088-7
Mousa, Shaker A. ; Bergh, Joel J. ; Dier, Emie ; Rebbaa, Abdelhadi ; O'Connor, Laura J. ; Yalcin, Murat ; Aljada, Ahmad ; Dyskin, Evgeny ; Davis, Faith B. ; Lin, Hung Yung ; Davis, Paul J. / Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. In: Angiogenesis. 2008 ; Vol. 11, No. 2. pp. 183-190.
@article{4d1b7fb0866245ed9e266f4f819fd392,
title = "Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor",
abstract = "Thyroid hormone has been recently shown to induce tumor growth and angiogenesis via a plasma-membrane hormone receptor on integrin αVβ3. The receptor is at or near the Arg-Gly-Asp (RGD) recognition site on the integrin that is important to extracellular matrix (ECM) protein and vascular growth factor interactions with the integrin. In the present study, we examined the possibility that tetraiodothyroacetic acid (tetrac), a deaminated, non-agonist thyroid hormone analog that binds to the integrin receptor, may modulate vascular growth factor-induced angiogenesis in the absence of thyroid hormone. Angiogenesis models were studied in which VEGF or FGF2 (1-2 μg/ml) induced tube formation in human dermal microvascular endothelial cells (HDMEC), stimulated new blood vessel branch formation in the chick chorioallantoic membrane (CAM) and induced angiogenesis in the mouse matrigel model. In all models, tetrac (1-10 μM) and at 10 μg in mouse matrigel inhibited the pro-angiogenesis activity of VEGF and FGF2 by more than 50{\%}. RT-PCR revealed that tetrac (1-3 μM) decreased abundance of angiopoietin-2 mRNA, but not angiopoietin-1 mRNA, in VEGF-exposed endothelial cells, suggesting that specific angiogenic pathways are targeted by tetrac. Tetrac is a novel, inexpensive small molecule whose anti-angiogenic activity in the present studies is proposed to reflect inhibition, via the integrin RGD recognition/thyroid hormone receptor site, of crosstalk between plasma-membrane vascular growth factor receptors and integrin αVβ3.",
keywords = "Angiogenesis, Growth factors, Integrin, Tetrac, Thyroid hormone",
author = "Mousa, {Shaker A.} and Bergh, {Joel J.} and Emie Dier and Abdelhadi Rebbaa and O'Connor, {Laura J.} and Murat Yalcin and Ahmad Aljada and Evgeny Dyskin and Davis, {Faith B.} and Lin, {Hung Yung} and Davis, {Paul J.}",
year = "2008",
month = "6",
doi = "10.1007/s10456-007-9088-7",
language = "English",
volume = "11",
pages = "183--190",
journal = "Angiogenesis",
issn = "0969-6970",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor

AU - Mousa, Shaker A.

AU - Bergh, Joel J.

AU - Dier, Emie

AU - Rebbaa, Abdelhadi

AU - O'Connor, Laura J.

AU - Yalcin, Murat

AU - Aljada, Ahmad

AU - Dyskin, Evgeny

AU - Davis, Faith B.

AU - Lin, Hung Yung

AU - Davis, Paul J.

PY - 2008/6

Y1 - 2008/6

N2 - Thyroid hormone has been recently shown to induce tumor growth and angiogenesis via a plasma-membrane hormone receptor on integrin αVβ3. The receptor is at or near the Arg-Gly-Asp (RGD) recognition site on the integrin that is important to extracellular matrix (ECM) protein and vascular growth factor interactions with the integrin. In the present study, we examined the possibility that tetraiodothyroacetic acid (tetrac), a deaminated, non-agonist thyroid hormone analog that binds to the integrin receptor, may modulate vascular growth factor-induced angiogenesis in the absence of thyroid hormone. Angiogenesis models were studied in which VEGF or FGF2 (1-2 μg/ml) induced tube formation in human dermal microvascular endothelial cells (HDMEC), stimulated new blood vessel branch formation in the chick chorioallantoic membrane (CAM) and induced angiogenesis in the mouse matrigel model. In all models, tetrac (1-10 μM) and at 10 μg in mouse matrigel inhibited the pro-angiogenesis activity of VEGF and FGF2 by more than 50%. RT-PCR revealed that tetrac (1-3 μM) decreased abundance of angiopoietin-2 mRNA, but not angiopoietin-1 mRNA, in VEGF-exposed endothelial cells, suggesting that specific angiogenic pathways are targeted by tetrac. Tetrac is a novel, inexpensive small molecule whose anti-angiogenic activity in the present studies is proposed to reflect inhibition, via the integrin RGD recognition/thyroid hormone receptor site, of crosstalk between plasma-membrane vascular growth factor receptors and integrin αVβ3.

AB - Thyroid hormone has been recently shown to induce tumor growth and angiogenesis via a plasma-membrane hormone receptor on integrin αVβ3. The receptor is at or near the Arg-Gly-Asp (RGD) recognition site on the integrin that is important to extracellular matrix (ECM) protein and vascular growth factor interactions with the integrin. In the present study, we examined the possibility that tetraiodothyroacetic acid (tetrac), a deaminated, non-agonist thyroid hormone analog that binds to the integrin receptor, may modulate vascular growth factor-induced angiogenesis in the absence of thyroid hormone. Angiogenesis models were studied in which VEGF or FGF2 (1-2 μg/ml) induced tube formation in human dermal microvascular endothelial cells (HDMEC), stimulated new blood vessel branch formation in the chick chorioallantoic membrane (CAM) and induced angiogenesis in the mouse matrigel model. In all models, tetrac (1-10 μM) and at 10 μg in mouse matrigel inhibited the pro-angiogenesis activity of VEGF and FGF2 by more than 50%. RT-PCR revealed that tetrac (1-3 μM) decreased abundance of angiopoietin-2 mRNA, but not angiopoietin-1 mRNA, in VEGF-exposed endothelial cells, suggesting that specific angiogenic pathways are targeted by tetrac. Tetrac is a novel, inexpensive small molecule whose anti-angiogenic activity in the present studies is proposed to reflect inhibition, via the integrin RGD recognition/thyroid hormone receptor site, of crosstalk between plasma-membrane vascular growth factor receptors and integrin αVβ3.

KW - Angiogenesis

KW - Growth factors

KW - Integrin

KW - Tetrac

KW - Thyroid hormone

UR - http://www.scopus.com/inward/record.url?scp=49949152481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49949152481&partnerID=8YFLogxK

U2 - 10.1007/s10456-007-9088-7

DO - 10.1007/s10456-007-9088-7

M3 - Article

C2 - 18080776

AN - SCOPUS:49949152481

VL - 11

SP - 183

EP - 190

JO - Angiogenesis

JF - Angiogenesis

SN - 0969-6970

IS - 2

ER -